Skip Navigation


Annals of Oncology Advance Access originally published online on January 12, 2009
Annals of Oncology 2009 20(3):498-502; doi:10.1093/annonc/mdn650
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/3/498    most recent
mdn650v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Spitaleri, G.
Right arrow Articles by De Cobelli, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spitaleri, G.
Right arrow Articles by De Cobelli, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

urogenital tumors

Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer

G. Spitaleri1,*,{dagger}, D. V. Matei2,{dagger}, G. Curigliano1, S. Detti2, F. Verweij2, S. Zambito2, E. Scardino2, B. Rocco2, F. Nolè1, L. Ariu1, T. De Pas1, F. de Braud1 and O. De Cobelli2

1 Division of Medical Oncology
2 Division of Urology, European Institute of Oncology, Milan, Italy

* Correspondence to: Dr G. Spitaleri, Division of Medical Oncology, European Institute of Oncology, Ripamonti 435, 20141 Milan, Italy. Tel: +39-02-57489 482; Fax: +39-02-57489-581; E-mail: gianluca.spitaleri{at}ieo.it

Background: There is a need for active agents with a better safety profile than docetaxel, yet good activity, for patients with hormone-refractory prostate cancer (HRPC). We carried out a phase II trial to determine the activity and safety of estramustine plus oral etoposide in HRPC.

Patients and methods: Patients were given estramustine (280 mg twice daily) and etoposide (100 mg/day, days 1–21) in 28-day cycles until disease progression or unacceptable toxicity. Primary end points were overall response rate and safety, as determined by prostrate-specific antigen (PSA) levels and lesion assessment.

Results: From November 2001 to February 2007, 75 patients were enrolled. All patients were assessable for safety; 17 (22.6%) had grade 3/4 toxicity. PSA response was assessable in 69, 14 of whom had a >50% reduction in PSA. Of 10 patients with one or more measurable lesions, two (20%) had partial response and two (20%) disease stabilization. Overall, median time to progression was 4.4 months (range 1 week–43 months); median survival was 23 months (range 3 weeks–64+ months).

Conclusions: Estramustine plus etoposide is active and has a manageable safety profile in patients with HRPC. In asymptomatic patients with nonaggressive disease this combination could be useful to delay the start of more demanding treatments.

Key words: estramustine phosphate, etoposide, hormone-refractory prostate cancer

{dagger} Both authors contributed equally to this work.

Received for publication May 15, 2008. Revision received September 1, 2008. Accepted for publication September 2, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.